Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

  1. Pal, S.K.
  2. Puente, J.
  3. Heng, D.Y.C.
  4. Glen, H.
  5. Koralewski, P.
  6. Stroyakovskiy, D.
  7. Alekseev, B.
  8. Parnis, F.
  9. Castellano, D.
  10. Ciuleanu, T.
  11. Lee, J.L.
  12. Sunela, K.
  13. O'Hara, K.
  14. Binder, T.A.
  15. Peng, L.
  16. Smith, A.D.
  17. Rha, S.Y.
Revue:
European Urology

ISSN: 1873-7560,  0302-2838

Année de publication: 2022

Volumen: 82

Número: 3

Pages: 283-292

Type: Article

DOI: 10.1016/J.EURURO.2021.12.024 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus